Topics

The Lancet Infectious Diseases: First clinical trial of antibody to neutralize henipaviruses finds it is safe and well tolerated in healthy volunteers

19:00 EST 2 Feb 2020 | AAAS

(The Lancet) The first ever treatment for preventing a group of viruses from causing potentially lethal infections has been tested in a phase I clinical trial, and was found to be safe and able to neutralize the viruses, according to results from 40 patients published in The Lancet Infectious Diseases journal. The trial was conducted in healthy participants and further trials will be needed to demonstrate its efficacy in infected patients.

Original Article: The Lancet Infectious Diseases: First clinical trial of antibody to neutralize henipaviruses finds it is safe and well tolerated in healthy volunteers

NEXT ARTICLE

More From BioPortfolio on "The Lancet Infectious Diseases: First clinical trial of antibody to neutralize henipaviruses finds it is safe and well tolerated in healthy volunteers"

Quick Search

Relevant Topics

Clincial Trials
In a clinical trial or interventional study, participants receive specific interventions according to the research plan or protocol created by the investigators. These interventions may be medical products, such as drugs or devices; procedures; or change...

Drug Discovery
Clinical Approvals Clinical Trials Drug Approvals Drug Delivery Drug Discovery Generics Drugs Prescription Drugs In the fields of medicine, biotechnology and pharmacology, drug discovery is the process by which drugs are dis...

Public Health
Alternative Medicine Cleft Palate Complementary & Alternative Medicine Congenital Diseases Dentistry Ear Nose & Throat Food Safety Geriatrics Healthcare Hearing Medical Devices MRSA Muscular Dyst...